You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 146 No. 2, February 1986 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  ORIGINAL INVESTIGATIONS
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on Web of Science (3)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Clinical Evaluation of Determinants of Glycemic Control

A New Approach Using Serum Glucose, C-Peptide, and Body Mass Indexes in Type II Diabetic Patients

Kwame Osei, MD

Arch Intern Med. 1986;146(2):281-285.


Abstract



• We evaluated the clinical characteristics and relationships between values of serum glucose, C-peptide, and body mass Index (BMI) in 40 type II diabetic patients. Patients were divided into three groups according to the drug therapy: group A (n =16), oral sulfonylurea agent; group B(n=16), insulin alone; and group C (n=8), combined insulin and oral agent. The relationships between the various factors were expressed as ratios (C-peptide/BMI, glucose/BMI, and C-peptide/glucose scores). Using glycosylated hemoglobin (HbA1) value of less than 10.5% to denote response to therapy, each group was subdivided into responders and nonresponders. Comparing the data in group A, mean (±SEM) fasting serum glucose levels were significantly lower in responders vs nonresponders. The mean HbA1 levels were 8.59±0.54% vs 12.34±0.34%, respectively. The C-peptide/BMI scores were 7.4 ±1.0 vs 8.14±1.2; C-peptide/glucose scores, 1.73 ± 0.27 vs 0.81 ±0.12; and glucose/BMI scores, 493±54 vs 1,082±168, respectively. The responders and nonresponders in group B had values similar to those of group A. Group C patients had data biochemically similar to those of the nonresponders in groups A and B. The responders in each group were characterized by serum glucose levels less than 200 mg/dL, C-peptide/glucose score greater than 1, and glucose/BMI score less than 700. The nonresponders had mean serum glucose levels greater than 200 mg/dL, C-peptide/glucose score less than 1, and glucose/ BMI score greater than 700. These simple calculated scores validate the importance of glucose/C-peptide/BMI interrelationships in ambulatory diabetic patients.

(Arch Intern Med 1986;146:281-285)



Author Affiliations



From the Division of Endocrinology and Metabolism, Department of Medicine, The Ohio State University Hospitals, Columbus.


Footnotes



Accepted for publication May 15, 1985.

Reprint requests to N-1120 Doan Hall, 410 W Tenth Ave, Columbus, OH 43210 (Dr Osei).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1986 American Medical Association. All Rights Reserved.